Evidence rather than costs must guide use of the implantable cardioverter defibrillator
Détails
ID Serval
serval:BIB_15E189632377
Type
Article: article d'un périodique ou d'un magazine.
Sous-type
Synthèse (review): revue aussi complète que possible des connaissances sur un sujet, rédigée à partir de l'analyse exhaustive des travaux publiés.
Collection
Publications
Institution
Titre
Evidence rather than costs must guide use of the implantable cardioverter defibrillator
Périodique
American Journal of Cardiology
ISSN
0002-9149 (Print)
Statut éditorial
Publié
Date de publication
11/2000
Volume
86
Numéro
9A
Pages
52K-57K
Notes
Journal Article
Review --- Old month value: Nov 2
Review --- Old month value: Nov 2
Résumé
Randomized controlled trials have shown superior survival rates with implantable cardioverter defibrillators (ICDs) compared with antiarrhythmic drugs in survivors of cardiac arrest and life-threatening ventricular tachyarrhythmias, as well as in high-risk patients with ischemic heart disease and inducible ventricular tachycardia (VT). Current defibrillators are small and implanted with techniques similar to standard pacemakers. They provide high-energy shocks for ventricular fibrillation (VF) and rapid VT, antitachycardia pacing for monomorphic VT, and antibradycardia pacing. Limited evidence suggests that ICD therapy is cost-effective when compared with other widely accepted treatments. The use of ICDs is likely to continue to expand in the future. Ongoing clinical trials will define further prophylactic indications of the ICD and clarify its cost-effectiveness ratio in different clinical settings.
Mots-clé
Cost-Benefit Analysis
Death, Sudden, Cardiac/etiology/*prevention & control
*Defibrillators, Implantable/economics
Electric Countershock/economics/*instrumentation
Humans
Patient Selection
Tachycardia, Ventricular/*therapy
Ventricular Fibrillation/*therapy
Pubmed
Web of science
Création de la notice
28/01/2008 11:09
Dernière modification de la notice
20/08/2019 13:45